NCT06788691View on ClinicalTrials.gov

Luspatercept for Clonal Cytopenias of Uncertain Significance

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 29, 2028

Conditions

CCUS Clonal Cytopenia of Undetermined SignificanceAnemiaLeukopeniaThrombocytopeniaNeutropenia

Interventions

DRUG

Luspatercept

Administered at 1 mg/kg once every 3 weeks

Trial Locations (1)

10021

RECRUITING

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER